Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs MANE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYRE Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 8–0 Matrix Metrics)

SYRE Overall Winner 6-Pillar Tally: SYRE 2 – 1 MANE (3 Tie) Matrix Metrics: SYRE 8 – 0 MANE

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) is the stronger overall head-to-head candidate over MANE (MANE) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 44.4/100 (HOLD) at $99.37 (N/M Forward P/E, 0.0% operating margin), whereas MANE carries 38.1/100 (SELL) at $128.05 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs MANE
SYRE NASDAQ Head-to-Head Winner
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.37
-4.45% 1D
Market Cap $9.9B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70
MANE US Equity
MANE
Institutional Equity
$128.05
-1.24% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.28β · 80% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $137.77 · SMA50: $122.82

6-Pillar Scorecard Institutional Category Breakdown (SYRE 2 – 1 MANE)

Columns: Metric · SYRE · MANE
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SYRE
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) -99.7% N/A
TTM Revenue (USD) N/A N/A
Market Cap $9.9B N/A
3. Profitability & Quality SYRE
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -35.0% N/A
4. Balance Sheet & Cash Flow MANE
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 87.9% (10th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (8) vs MANE (0)
Institutional Metric SYRE MANE Criterion Row Edge
Market Capitalization
Scale
$9.9B N/A Larger Scale SYRE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth SYRE
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin SYRE
Net Profit Margin
Profitability
0.0% N/A Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
-35.0% N/A Higher ROE SYRE
52-Week Range Position
Momentum
87% ($22–$111) 77% ($32–$157) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.74β · 59% Vol 1.28β · 80% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
44.4 / 100 (HOLD) 38.1 / 100 (SELL) Higher Composite SYRE
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +6.7 pp
SYRE: +24.37% · MANE: +17.67%
3M Horizon MANE +22.88 pp
SYRE: -7.84% · MANE: +15.04%
6M Horizon SYRE +14.23 pp
SYRE: +41.8% · MANE: +27.57%
1Y Horizon MANE +29.36 pp
SYRE: +209.85% · MANE: +239.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs MANE. Trailing 12-month operating profitability (SYRE 0.0% vs MANE N/A) and valuation multiples (SYRE N/M vs MANE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
MANE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MANE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MANE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.9B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MANE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SYRE vs MANE Key Questions & Quantitative Answers

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) is the stronger overall head-to-head candidate over MANE (MANE) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 44.4/100 (HOLD) at $99.37 (N/M Forward P/E, 0.0% operating margin), whereas MANE carries 38.1/100 (SELL) at $128.05 (N/M Forward P/E, N/A operating margin). Technically, SYRE sits in a Neutral phase (RSI 53.5, UNCLASSIFIED options structure) and MANE sits in a Neutral phase (RSI 47.0, UNCLASSIFIED options structure).

SYRE leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MANE at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus N/A for MANE. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MANE.

SYRE and MANE trade at balanced relative valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MANE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus MANE (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.74β · 59% Vol realized risk). By comparison, MANE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.28β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.